Table 1

Summary of key details of papers included

SourceStudy designAccessTreatmentnAge (years)Male genderComorbidities% StenosisLength of stenosis (cm)Success (%)*Target lesion/area primary patency (%)Loss of target lesion/area primary patency (%)Loss of access circuit primary patency (%)
Haskal et al11RCT (multisite)AVGAngioplasty9359.8±13.636 (38.7%)HTN: 87 (93.5%)
DM: 58 (62.4%)		72.9±93.78±1.2773.13 months: 77.2
6 months 23.3
1 year: NR
2 years: NR		3 months: 22.8
6 months: 76.7
1 year: NR
2 years: NR		6 months: 66.7
Covered stents (brand)97 (Flair)61.8±14.636 (37.1%)HTN: 96
(99.0%)
DM: 59 (60.8%)		70.9±10.53.53±1.3993.83 months: 80.2
6 months: 50.6
1 year: NR
2 years: NR		3 months: 19.8
6 months: 49.5
1 year: NR
2 year: NR		6 months: 49.4
Rajan and Falk12RCT (multisite)AVFAngioplasty552.2±11.44
(80.0%)		HTN: NR
DM: 3 (60.0%)		NRNR
(range given only)		1003 months: 60
6 months: 0
1 year: 0
2 years: NR		3 months: 40
6 months: 100
1 year: 100
2 years: NR		3 months: 80
6 months: 100
12 months:100
Covered stents (brand)9
(V)		66.6±11.32
(22.2%)		HTN: NR
DM: 6 (66.7%)		NRNR
(range given only)		1003 months: 100
6 months: 100
1 year: 29
2 years: NR		3 months: 0
6 months: 0
1 year: 71
2 years: NR		3 months: 0
6 months: 33
12 months: 78
Haskal et al13RCT (multi-site)AVGAngioplasty13263.1±12.346 (34.8%)NR69.1±13.31.98±1.49753 months: NR
6 months: NR
1 year: 24.8
2 years: 13.5		3 months: NR
6 months: NR
1 year: 75.2
2 years: 86.5		12 months: 89
24 months: 94.5
Covered stents (brand)138
(Flair)		63.2±13.246 (33.3%)NR69.4±12.22.17±1.4881.23 months: NR
6 months: NR
1 year: 47.6
2 year:91 26.9		3 months: NR
6 months: NR
1 year: 53.4
2 years: 73.1		12 months: 76
24 months: 90.5
Vesely et al14RCT (multisite); effectiveness-per-protocol data usedAVGAngioplasty13861±1568 (49.3%)HTN: 134
(97.1%)
DM: 90
(65.2%)		74±132.5±2.3843 months: NR
6 months: 34.2
1 year: 18.2
2 years: 9.9		3 months: NR
6 months: 65.8
1 year: 81.8
2 years: 90.1		6 months: 70.6
12 months: 84.8
24 months: 93.2
Covered stents (brand)131
(V)		63±1361 (46.6%)HTN: 129 (98.5%)
DM: 84 (64.1%)		72±132.3±2.11003 months: NR
6 months: 52.9
1 year: 30.2
2 years: 15.7		3 months: NR
6 months: 47.1
1 year: 69.8
2 years: 84.3		6 months: 56.6
12 months: 78.6
24 months: 90.4
Kaván et al15RCT (single-site); overlapped with 2019 studyAVGAngioplasty1363±192
(15.4%)		HTN: 5
(38.5%)
DM: 4 (30.8%)		NRNRNR3 months: NR
6 months: 8
1 year: N/A†
2 years: N/A		3 months: NR
6 months: 92
1 year: N/A†
2 years: N/A†		NR
Covered stents (brand)17
(Flu)		67±136
(35.3%)		HTN: 12
(70.6%)
DM: 6 (35.3%)		NRNRNR3 months: NR
6 months: 47
1 year: N/A†
2 years: N/A†		3 months: NR
6 months: 53
1 year: N/A†
2 years: N/A†		NR
Yang et al16RCT (single site)AVGAngioplasty4963.4±14.615 (30.6%)HTN: 24
(49.0%)
DM: 14
(28.6%)		71±122.87±2.777.53 months: 65.3
6 months: 27.8
1 year: 7.8
2 years: NR		3 months: 34.7
6 months: 72.2
1 year: 92.2
2 years: NR		NR
Covered stents (brand)49
(V)		65.7±10.912
(24.5%)		HTN: 31
(63.6%)
DM: 19
(38.8%)		69±105.16±4.81003 months: 91.7
6 months: 83.2
1 year: 46.9
2 years: NR		3 months: 8.3
6 months: 16.8
1 year: 53.1
2 years: NR		NR
Kavan et al17RCT (single site), overlapped with 2016 study†AVGAngioplasty2061±175
(25.0%)		HTN: 15
(75.0%)
DM: 9
(45.0%)		66±16NR1003 months: NR
6 months: NR
1 year: 0
2 years: 0		3 months: NR
6 months: NR
1 year: 100
2 years: 100		NR
Covered stents (brand)20
(Flu)		65±135
(25.0%)		HTN: 17
(85.0%)
DM: 7
(35.0%)		67±9NR1003 months: NR
6 months: NR
1 year: 65
2 years: 37		3 months: NR
6 months: NR
1 year: 35
2 years: 63		NR
AveNEW (ongoing)
18		RCT (multisite)AVFAngioplasty13862±11.584
(60.9%)		HTN: 133
(96.4%)
DM: 94
(68.1%)		NR2.97±1.798.43 months: NR
6 months: 47.9
1 year: 21.2
2 years: ongoing		3 months: NR
6 months: 52.1
1 year: 78.8
2 years: ongoing		12 months: 83.3
Covered stents (brand)142
(Cov)		63±13.289
(62/7%)		HTN: 139
(97.9%)
DM: 101
(71.1%)		NR2.88±1.7498.63 months: NR
6 months: 78.7
1 year: 57.5
2 years: ongoing		3 months: NR
6 months: 21.3
1 year: 42.5
2 years: ongoing		12 months: 71.1

  • *Interchangeable terms for success, specifically defined as ≤30% residual stenosis, used in different studies (anatomic, technical and acute procedural).

  • †Data overlapped with later study.

  • AVF, arteriovenous fistula; AVG, arteriovenous graft; Cov, Covera; DM, diabetes mellitus; Flu, Fluency; HTN, hypertension; N/A, not applicable; NR, not reported; RCT, randomised controlled trial; V, Viabahn.